Request Demo

Last update 03 Apr 2026

Alprazolam

Last update 03 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryAlprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care.

Drug Type

Small molecule drug

Synonyms

8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Alprazolcem, AP-1002

+ [19]

Target

DOCK5 x GABAA receptor

Action

inhibitors, agonists

Mechanism

DOCK5 inhibitors(dedicator of cytokinesis 5 inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

DyssomniasCatatoniaDepressive Disorder+ [7]

Inactive Indication

Drug abuseEpilepsies, MyoclonicMild asthma+ [1]

Originator Organization

Takeda Pharmaceutical Co., Ltd.Upjohn Pharmaceuticals Ltd.

Active Organization

Unimed Pharmaceutical, Inc.UCB Pharma SA

UCB SA

+ [6]

Inactive Organization

VIATRIS Pharmaceuticals Ltd.

Engage Therapeutics, Inc.

UCB, Inc.

+ [4]

License Organization

Alexza Pharmaceuticals, Inc.

Lee's Pharmaceutical Holdings Ltd.

Engage Therapeutics, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (16 Oct 1981),

Anxiety DisordersPanic Disorder

RegulationBreakthrough Therapy (China)

Structure/Sequence

Molecular FormulaC17H13ClN4

InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N

CAS Registry28981-97-7

132

Clinical Trials associated with Alprazolam

NCT07275710

/ Not yet recruitingNot ApplicableIIT

Role of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment

To compare mean pain score between two group of participants undergoing post operative pain management after single visit root canal treatment: one group receiving NSAIDs alone and the other receiving a combination of NSAIDs and an anxiolytic medication i.e alprazolam.

Start Date01 Feb 2026

Sponsor / Collaborator-

NCT07154147

/ RecruitingPhase 4IIT

Cataract Oral vs IV Sedation Pilot RCT: A Non-inferiority Assessment of Perioperative Safety and Cognitive Recovery in Older Adults

The goal of this clinical trial is to find out if taking a pill (oral sedation) works just as well as getting medicine through a vein (IV sedation) to help older adults feel relaxed during cataract surgery. We are also studying how these two methods affect recovery, especially thinking and memory after surgery, and how satisfied people are with their care. Participants in this study will be randomly assigned to receive either oral sedation (+ IV placebo) or IV sedation (+ oral placebo) before their cataract surgery. They will complete short surveys about their thinking and recovery before and after surgery, and will be contacted by phone after surgery to check on their recovery. The results of this study will help doctors understand if a simple pill can be a safe and effective alternative to IV sedation for cataract surgery.

Start Date12 Aug 2025

Sponsor / Collaborator

The University of California, San Francisco

NCT07020988

/ CompletedPhase 1

An Open Label, Single Dose, Randomized, Active Comparator, Quantitative Electroencephalogram Crossover Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Intravenous Midazolam and of Staccato Alprazolam Versus Nasal Diazepam in Healthy Study Participants

The purpose of this study is to estimate the difference in the time to onset of action between Staccato alprazolam and intravenous (iv) midazolam using changes in power in the combined spindle and β1 frequency bands in the qEEG (quantitative electroencephalogram).

Start Date12 Jun 2025

Sponsor / Collaborator

UCB Biopharma SRL

100 Clinical Results associated with Alprazolam

100 Translational Medicine associated with Alprazolam

100 Patents (Medical) associated with Alprazolam

4,907

Literatures (Medical) associated with Alprazolam

01 Jun 2026·PULMONARY PHARMACOLOGY & THERAPEUTICS

Pulmonary safety of Staccato alprazolam in healthy participants and participants with mild asthma: Phase 1, randomized, double-blind, placebo-controlled trial

Article

Author: Barlow, Laura ; LaForce, Craig F ; Chanteux, Hugues ; Miller, S David ; Burian, Maria ; Watanabe, Shikiko ; King, Aliceson

Staccato alprazolam (STAP) is a hand-held device that can provide rapid systemic delivery of alprazolam via pulmonary inhalation. UP0099/NCT04802746, a phase 1, randomized, double-blind, placebo-controlled trial, evaluated pulmonary safety of two consecutive doses of STAP administered 72 h apart (days 1, 4). Part A evaluated STAP 1 mg and 2 mg vs. placebo in a three-way crossover design in healthy adults. Part B evaluated STAP 2 mg vs. placebo in a two-arm parallel-group design in adults with mild asthma. In Part A (n = 30 randomized) on day 1, mean change from baseline in forced expiratory volume in 1 s (FEV₁) showed a statistically significant decrease vs. placebo at 5 min postdose for STAP 1 mg and 5/20 min for STAP 2 mg. On day 4, there were no statistically significant negative changes from baseline in FEV₁. Respiratory treatment-emergent adverse events (TEAEs) were reported by 8/29 and 12/29 participants on STAP 1 mg/2 mg, respectively (day 1), and 8/29 and 9/28 (day 4) (placebo: 0). In Part B (n = 25 placebo, n = 23 STAP) on days 1 and 4, mean change from baseline in FEV₁ showed a statistically significant decrease for STAP 2 mg vs. placebo at 5/20 min and 6 h postdose. Respiratory TEAEs were reported by 16/23 participants on STAP 2 mg on day 1, 15/22 on day 4 (placebo: 0). Most respiratory TEAEs were mild in intensity. No evidence of clinically relevant airway obstruction or respiratory TEAEs indicative of bronchospasm with STAP were observed. Two doses of STAP (1 mg/2 mg) administered 72 h apart were well tolerated in healthy participants and those with mild asthma.

01 Apr 2026·PHYSIOLOGY & BEHAVIOR

Kratom (Mitragyna speciosa) alkaloids influence on cardiopulmonary measures and high-fat diet-induced weight gain in mice

Article

Author: Elango, Arul ; Bello, Nicholas T ; Sweeney, Adrianna M ; Bernstein, Emma ; Vasilatis, Ariane ; Simon, James E ; Fields, Spencer E ; Akgun, Elif Ece ; Wu, Qingli ; Carry, Eileen

Kratom (Mitragyna speciosa) has been marketed and used for a variety of health-promoting applications. Kratom contains an expansive bioactive alkaloid profile with mitragynine (MTG) as the most abundant. Individual responses to kratom have been reported, but the role of obesity as a factor influencing the effects of kratom has not been studied. First, we used a standardized kratom extract (KE) to determine the cardiopulmonary differences with KE (290, 500 mg/kg) and matched MTG (18 mg/kg) in high-fat diet (HFD; 45% Fat) induced obese male C57Bl/6 J mice. As measured by whole-body plethysmography, acute oral dosing revealed an approximate 15% reduction in the respiratory rate with all doses of KE and MTG. Unlike a well-known respiratory depressant, alprazolam, KE and MTG did not reduce minute ventilation (MvB; ml/min). As measured by volume-pressure recordings, KE 500 mg/kg produced an approximate 12% reduction in heart rate in normal weight mice. Second, we determined whether daily oral dosing KE (50, 150 mg/kg) prevented HFD-induced weight gain. Daily 150 mg/kg resulted in an increase in body weight gain (∼1 g) in the last week after 21 days of dosing. After 4 days following kratom cessation, there was reduced distance traveled in the KE 150 mg/kg compared with the KE 50 mg/kg group in an elevated plus maze test. These findings demonstrate a dose-dependent-increase in weight gain with KE, suggesting further investigation is needed to delineate kratom alkaloid effects on metabolism and body weight control.

01 Apr 2026·JOURNAL OF ANXIETY DISORDERS

Efficacy and safety of etifoxine versus alprazolam in generalized anxiety disorders with somatic symptoms: A randomized, double-blind, comparative study

Article

Author: Kumar, Ashutosh ; Neeli, Uma Jyothi ; Dutta, Mithun ; Mohide, Ashish ; Dalaya, Nitin ; Mehta, Suyog ; Joglekar, Sadhna ; Thaker, Spandan ; Chaudhari, Dhananjay ; Ganesan, Gopalakrishnan ; Mukhopadhyay, Asish ; Prabhakar, Kalmegh ; Behera, Sapan ; Shaikh, Raisa ; Saha, Shruti ; Patil, Dipak ; Devkare, Prashant ; Pandit, Sucheta ; Sonowal, Supriya ; Rajendra, Rajagopal ; Ghadge, Pravin ; Patil, Bharati ; Lakhwani, Lalit

Etifoxine, a non-benzodiazepine anxiolytic, is useful for managing anxiety symptoms. However, its role in managing somatic symptoms in generalized anxiety disorder (GAD) remains unclear. Hence, we aimed to compare the efficacy and safety of Etifoxine with Alprazolam in adults with GAD with somatic symptoms. This phase 3, randomized, double-blind, double-dummy study included 260 patients aged 18-65 years with GAD with somatic symptoms who received either Etifoxine 50 mg TID or Alprazolam 0.5 mg TID (1:1) for 4 weeks. The primary outcome was the change from baseline to day 28 in the Hamilton Anxiety Rating Scale (HAM-A) total score. Secondary efficacy outcomes included changes from baseline to days 7 and 14 in HAM-A total score, changes from baseline to days 7, 14, and 28 in HAM-A psychic and somatic sub-scores, clinical global impression-severity score, and percentage of patients with clinical and patient global impression-improvement scale responses. Our study results indicated that both Etifoxine and Alprazolam demonstrated significant improvements in mean change in HAM-A total scores at day 28 from baseline [mean (SD): -13.5 (4.21) and -13.4 (4.64), respectively; p < 0.0001 for both]. The adjusted mean difference (95% CI) was -0.18 (-1.08, 0.72), indicating non-inferiority of Etifoxine. Changes in secondary efficacy parameters were also comparable between groups. Treatment-emergent AEs were mild and observed in 10% and 7.7% of patients in the Etifoxine and Alprazolam groups, respectively. Etifoxine was non-inferior to Alprazolam in reducing anxiety symptoms in GAD, was well-tolerated, and can be a promising alternative for anxiety management without drug dependence risk.

News (Medical) associated with Alprazolam

08 Mar 2026

·www.einpresswire.com

Alternative to Meds Center Highlights Drug-Free Xanax Alternatives and Safer Benzodiazepine Discontinuation Support

Sedona inpatient program emphasizes gradual tapering, seizure-risk awareness, and holistic strategies to address anxiety at its source Safe discontinuation requires gradual reduction, medical monitoring, and a plan that supports both nervous system stabilization and the underlying contributors to anxiety.” — Alternative to Meds Center SEDONA, AZ, UNITED STATES, March 8, 2026 / EINPresswire.com / -- Alternative to Meds Center (ATMC) is expanding public awareness around drug-free Xanax alternatives and the importance of medically supervised benzodiazepine tapering for individuals seeking safer recovery from alprazolam dependence. The center’s clinical team emphasizes that anxiety relief and medication discontinuation should be approached as separate—but connected—goals, requiring individualized planning, medical oversight, and evidence-informed holistic support. Xanax (alprazolam) is a benzodiazepine commonly prescribed for anxiety and panic-related symptoms. While some individuals begin Xanax hoping for quick relief, many later discover the medication can be difficult to stop and may introduce a wide range of adverse effects. ATMC reports that one of the most common challenges is that discontinuation can be complicated by rebound anxiety, sleep disruption, and neurological instability—especially when reduction occurs too quickly or without appropriate safeguards. “Stopping benzodiazepines abruptly can be extremely dangerous,” said a representative of Alternative to Meds Center. “Safe discontinuation requires gradual reduction, medical monitoring, and a plan that supports both nervous system stabilization and the underlying contributors to anxiety.” The Role of Xanax Alternatives Depends on the Goal ATMC notes that the most effective way to use Xanax alternatives depends on an individual’s end goal: For those seeking to avoid starting benzodiazepines: drug-free strategies may help stabilize symptoms and support mental wellness without introducing dependence risks. For those already prescribed Xanax and seeking to stop: alternatives can be used before, during, and after tapering to support resilience and reduce symptom burden while dosage is gradually reduced. The center strongly cautions against abrupt cessation and encourages individuals to work with a qualified medical professional experienced in benzodiazepine tapering. Gradual reduction is widely considered the safest and most reliable approach, especially for long-term users or individuals who have experienced withdrawal symptoms in the past. Protracted Withdrawal and Why Tapering Must Be Individualized ATMC also highlights a lesser-discussed risk: protracted discontinuation symptoms, in which withdrawal-related effects persist beyond the expected timeframe. While not inevitable, prolonged symptoms may occur when benzodiazepines are stopped too quickly, at too steep a reduction rate, or without adequate support. Because of the seizure risk associated with benzodiazepine withdrawal , ATMC encourages individuals and families to treat tapering as a medically significant process—one that should include monitoring, stabilization planning, and coordinated support. The center also references established clinical literature describing benzodiazepine withdrawal phenomena and the need for cautious dose reduction approaches. A “Root-Cause” Framework for Anxiety Support Alternative to Meds Center emphasizes that “Xanax alternatives” should not be interpreted as simply replacing one medication with another. Instead, the center’s approach focuses on identifying and addressing contributing factors that may worsen anxiety and sleep disturbance, such as: • nutritional deficiencies and metabolic imbalance • inflammatory triggers and microbiome disruption • toxin exposure burdens, including environmental irritants • chronic sleep impairment and circadian disruption • unresolved stress load and psychological trauma patterns Through its inpatient programs, ATMC integrates lab assessment and supportive therapies intended to stabilize the body and reduce symptom drivers without relying on sedative medications for relief. Examples of Drug-Free Alternatives Used in Integrative Care ATMC’s clinical framework incorporates a range of non-pharmaceutical approaches that may be discussed with a qualified prescriber and treatment team, including: • nutrition-centered therapy and whole-food dietary improvement • support for healthy gut microbiome balance • lifestyle strategies to reduce environmental and chemical exposures • sleep hygiene protocols to improve restorative sleep • physical therapies such as massage, acupuncture, and exercise • counseling approaches including CBT and other structured therapies • adjunctive services that support emotional processing and resilience In some cases, individuals also explore carefully selected supplements or amino-acid-based supports under professional guidance—particularly when the goal is to reduce nervous system over-activation during tapering. ATMC emphasizes that supplements should be chosen conservatively and coordinated with a clinician, especially during medication reduction. Inpatient Support Designed for Safety and Stability ATMC provides inpatient support for clients tapering from benzodiazepines and other psychiatric medications, offering structured monitoring and a calm environment designed to reduce stressors that can aggravate withdrawal symptoms. The program model includes 24/7 oversight, individualized planning, and a broad array of integrative services that support stabilization. The center reports that many clients arrive feeling discouraged by previous tapering attempts or misinformed about the challenges of discontinuation. ATMC’s approach emphasizes education, medical safety, and practical strategies to reduce both withdrawal distress and the anxiety that can remain even after a medication is removed. “Many people want to eliminate the Xanax—but they also need a plan to eliminate the anxiety,” the ATMC representative added. “That’s where individualized, drug-free, whole-person support can make a meaningful difference.” Addressing Rising Risks and the Need for Safer Options As benzodiazepine misuse and overdose trends remain a public health concern, ATMC encourages individuals experiencing dependence, tolerance, or adverse reactions to seek professional help. Drug-free alternatives—along with gradual tapering support—may help individuals regain stability and reduce reliance on sedative medications while improving overall health. To learn more about Alternative to Meds Center’s inpatient approach to benzodiazepine tapering and drug-free Xanax alternatives, contact the admissions team for program information, insurance options, and next steps. Alternative to Meds Center Alternative to Meds Center +1 877-503-0770 email us here Visit us on social media: LinkedIn Instagram Facebook YouTube TikTok X Other Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

04 Mar 2026

·www.pharmaceutical-technology.com

Aspire Biopharma and Microsize collaborate for alprazolam powder formulation

Microsize specialises in particle size reduction, micronisation, and solubility enhancement for drugs. Credit: Komsan Loonprom / Shutterstock.com. Aspire Biopharma has entered a strategic partnership with Microsize to advance the development of a new sublingual powder formulation of alprazolam, targeting rapid anxiety relief. Alprazolam is the active pharmaceutical ingredient (API) in Xanax, a commonly prescribed anti-anxiety medication. Traditional oral alprazolam tablets can require 25 minutes or more to take effect, as absorption occurs through the gastric system and liver. Aspire Biopharma’s new sublingual powder is designed to bypass the digestive tract and will deliver alprazolam directly into the bloodstream for faster and more predictable relief of anxiety disorders and panic attacks. Microsize focuses on reducing particle sizes, micronisation, and enhancing solubility for drugs. In addition to this development, Aspire Biopharma has partnered with Pace to handle drug-excipient compatibility, development of the formulation, batch manufacturing, and stability studies. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The company’s sublingual delivery technology offers precise and rapid delivery of drugs by directly entering the bloodstream while avoiding gastrointestinal absorption. It can be applied across multiple APIs and bioactive substances, including supplements and small-molecule therapeutics. Aspire Biopharma interim CEO Kraig Higginson said: “Our collaboration with Microsize is a critical milestone in bringing a modern, fast-acting alternative to millions of patients suffering from anxiety. “Microsize’s unparalleled expertise in particle engineering, together with the support of Pace, a leading testing and analytical lab, will allow us to optimise our sublingual powder, accelerating our journey toward a Phase I clinical trial planned for mid-2026. We are aiming to be the first alprazolam sublingual product on the market.” Microsize operates from 100,000ft² of US Food and Drug Administration (FDA)-inspected US-based current good manufacturing practice (cGMP) facilities.

03 Mar 2026

·www.biospace.com

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset formulation planned for mid-2026. Alprazolam remains a top 40 prescribed medication in the US, with over 15.8 million prescriptions in 2023. ESTERO, FL / ACCESS Newswire / March 3, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted, patent-pending drug delivery technology, today announced a strategic partnership with Microsize (Quakertown, Pennsylvania), the largest independent North American contract development and manufacturing organization (CDMO) focused on cGMP micronization and particle size engineering. Aspire has engaged Microsize to accelerate the development of a novel sublingual powder formulation of alprazolam, the active pharmaceutical ingredient (API) in the widely prescribed anti-anxiety medication Xanax ® . Addressing the Need for Faster Relief Although traditional oral alprazolam tablets are highly effective, they can take 25 minutes or more to take effect as they pass through the gastric system and liver. Aspire's novel sublingual formulation is designed to bypass the digestive tract, delivering the medication directly into the bloodstream for faster, more predictable relief of anxiety disorders and panic attacks. "Our collaboration with Microsize is a critical milestone in bringing a modern, fast-acting alternative to millions of patients suffering from anxiety" said Kraig Higginson, Interim CEO of Aspire Biopharma. "Microsize's unparalleled expertise in particle engineering, together with the support of Pace®, a leading testing and analytical lab, will allow us to optimize our sublingual powder, accelerating our journey toward a Phase 1 clinical trial planned for mid-2026. We are aiming to be the first alprazolam sublingual product on the market." Industry-Leading Technical Collaboration Microsize specializes in particle size reduction, micronization, and solubility enhancement for drugs. To complement this development, Aspire has also engaged Pace®, a leading science and technology company with a nationwide network of laboratories, to manage drug-excipient compatibility, formulation development, batch manufacturing, and stability studies. Market Opportunity Alprazolam was the 37th most commonly prescribed medication in the United States in 2023, with over 15.8 million combined branded and generic prescriptions. According to Research and Markets , the global alprazolam powder market is projected to reach $55.84 billion by 2032, driven by increasing prevalence of anxiety, a growing geriatric population, and the demand for enhanced drug delivery systems. About Microsize For over 30 years, Microsize has been a pioneer in enhancing dissolution and bioavailabilty of Active Pharmaceutical Ingredients (API's) and functional excipients via particle size reduction technologies including milling, micronization and classification. Operating from 100,000 square feet in US-based, state-of-the-art, FDA inspected GMP facilities, Microsize has the experience and capabilities to rapidly develop, scale up, and process API's and excipients ranging from grams to multi-metric tons, including highly potent compounds. Microsize is the partner of choice from small biotechs to big pharma to CDMO's, and is recognized for its speed, responsiveness, and high customer-touch business model. Visit . About Aspire Biopharma Holdings, Inc. Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning small molecule therapeutics, nutraceuticals and supplements. For more information, please visit Aspire Biopharma Holdings, Inc. Contact PCG Advisory Kevin McGrath +1-646-418-7002 kevin@pcgadvisory.com Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release. SOURCE: Aspire Biopharma Holdings, Inc. View the original press release on ACCESS Newswire

Phase 1

100 Deals associated with Alprazolam

External Link

KEGG	Wiki	ATC	Drug Bank
D00225	Alprazolam	N05BA12	DB00404

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dyssomnias	South Korea	Unimed Pharmaceutical, Inc.	13 Mar 2025
Catatonia	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Depressive Disorder	Japan	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Depressive Disorder	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	Teva Takeda Pharma Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	T’s Pharma Co., Ltd.	15 Feb 1984
Sleep Initiation and Maintenance Disorders	Japan	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Anxiety Disorders	United States	Upjohn US 2 LLC	16 Oct 1981
Panic Disorder	United States	Upjohn US 2 LLC	16 Oct 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy	Phase 3	Belgium	UCB SA	30 Jan 2022
Epilepsy, Absence	Phase 3	United States	UCB Trading (Shanghai) Co., Ltd.	07 Dec 2021
Epilepsy, Absence	Phase 3	United States	UCB Pharma SA	07 Dec 2021
Epilepsy, Absence	Phase 3	United States	Alexza Pharmaceuticals, Inc.	07 Dec 2021
Epilepsy, Absence	Phase 3	Japan	Alexza Pharmaceuticals, Inc.	07 Dec 2021
Epilepsy, Absence	Phase 3	Japan	UCB Trading (Shanghai) Co., Ltd.	07 Dec 2021
Epilepsy, Absence	Phase 3	Japan	UCB Pharma SA	07 Dec 2021
Epilepsy, Absence	Phase 3	Australia	UCB Pharma SA	07 Dec 2021
Epilepsy, Absence	Phase 3	Australia	UCB Trading (Shanghai) Co., Ltd.	07 Dec 2021
Epilepsy, Absence	Phase 3	Australia	Alexza Pharmaceuticals, Inc.	07 Dec 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05626439 (P9-9.009, AAN2025)	Phase 1	Seizures	21	Staccato Alprazolam 2mg	zenkfymrjc(mwgvzhcptd) = eygiswmtri rcohvvsiym (khsgxfdrcm )	Positive	07 Apr 2025
				Oral Alprazolam 2mg	zenkfymrjc(mwgvzhcptd) = bruqykmsvu rcohvvsiym (khsgxfdrcm )
NCT04782388 (UP0101, AAN2024)	Phase 1	-	-	Staccato Alprazolam 2 mg	iyrpbcjepp(vxoyqgmfqk) = AUC0-t showed a similar trend to AUCinf enkjbwftes (fhslnhlfwl ) View more	Positive	09 Apr 2024
				Staccato Placebo
NCT04970342 (PDID, CTgov)	Phase 1	-	13	Placebo (Lactose) Capsule+CBD+THC ("Sober" or Double Placebo)	uskoqrxliw(ambqhthbno) = rzaxcixtlm kvljbiuiap (vlgmtlhjdy, 5.737) View more	-	25 Jul 2023
				CBD+0.75 mg Alprazolam Capsule+THC (Active Alprazolam (Xanax), Placebo Cannabis)	uskoqrxliw(ambqhthbno) = rmqqidpoie kvljbiuiap (vlgmtlhjdy, 6.434) View more
NCT03478982 (ENGAGE-E-001, Pubmed)	Phase 2	Epilepsy	116	Staccato® alprazolam 1.0 mg	pqeypgjdbb(snwhtudvye) = avkgerwfru adpqfkxpwx (rqylmnwvry )	-	21 Oct 2022
				Staccato® alprazolam 2.0 mg	pqeypgjdbb(snwhtudvye) = adiknuoiay adpqfkxpwx (rqylmnwvry )
NCT02351115 (CTgov)	Phase 2	Epilepsy	5	placebo (Inhaled Placebo)	atvlyshwll(oyfqupctjv) = ttoysiasfh cwqrdkpiet (lhknbjwjms, fhwycusaim - vebugfulvu) View more	-	10 Aug 2021
				Staccato+Alprazolam (Staccato Alprazolam, 0.5 mg)	atvlyshwll(oyfqupctjv) = zufkzcibae cwqrdkpiet (lhknbjwjms, pnxxsrykdp - feiplnbwpq) View more
NCT03478982 (StATES \| P1.5-023 \| ENGAGE-E-001, CTgov)	Phase 2	Seizures \| Epilepsy \| Epilepsies, Myoclonic	156	Staccato Alprazolam (STAP-001) (Open-label: Staccato Alprazolam (STAP-001) 1.0 Milligram (mg))	tqwoknjhdu = eadjsxhyjg tfxapdiysb (cxfipzullr, buufilsinu - aroeqsighd) View more	-	03 Feb 2021
				placebo+alprazolam (Double-blind: Placebo)	tqwoknjhdu = kevptfnnde tfxapdiysb (cxfipzullr, ovatrtofna - ahchaqxbcq) View more
NCT03297944 (CTgov)	Phase 4	Psychomotor Disorders	15	Placebo (PLC/PLC)+ZOL+PLC+Alprazolam+Zolpidem+ALC	rabtxksuhh(lsbgjllgrp) = ncjhkohcoj ckxfumutil (plhxtvovjd, cvzpbqzabq - mvqcecupnx) View more	-	29 Jan 2020
NCT00603980 (CTgov)	Phase 1	Drug abuse	31	placebo (Placebo)	vutwahrcoc(qysoqbnebn) = agcpenodej whwagunyzz (cmdcywvlmr, 0.349) View more	-	02 Jan 2020
				Alprazolam (Oral Alprazolam 1 mg)	vutwahrcoc(qysoqbnebn) = jgyktbkivc whwagunyzz (cmdcywvlmr, 0.349) View more
NCT00662259 (GAD, CTgov)	Phase 4	Generalized anxiety disorder	32	Xanax (Alprazolam)	eilndjtmva(qsstuthrzv) = qplmzzkuan rozvlaxhwh (kvhfclipyz, .1529) View more	-	25 Jul 2019
				Placebo (Placebo)	eilndjtmva(qsstuthrzv) = dmcoicqsox rozvlaxhwh (kvhfclipyz, .1123) View more
NCT03478982 (P1.5-023, AAN2019)	Phase 2	Epilepsy	8	Staccato Alprazolam 1 mg	briaqnvrip(dbidphvzfz) = no adverse events were serious or severe nntvlejykl (qnwoquosvy )	Positive	09 Apr 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Alprazolam

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation